However some analysts feel, the most crucial suggestion is the creation of a Rs 50,000-crore BioEconomy Growth Fund for 2026-2035 to bridge what the report terms the “valley of death” between laboratory innovation and commercial-scale manufacturing. The proposed fund would provide blended finance, catalytic equity and infrastructure support for biomanufacturing, advanced therapeutics, diagnostics, fermentation platforms, biomaterials and synthetic biology ventures-which many believe is the need of the hour and are hopeful will result in a bright future for the sector.
